heart failure (CHF). Since catecholamines alter immune function, we asked whether fl-blocker treatment leads to enhancement of immune function. Methods and Results Fifteen patients with New York Heart Association class III-IV CHF secondary to dilated cardiomyopathy were titrated to a minimum dose of metoprolol 25 mg BID on a background therapy of digoxin, diuretic, and angiotensin-converting enzyme inhibitors. Cardiac and immunologic studies were done before and 6 months to 1 year after treatment. While these patients served as their own controls, an additional population of patients with heart failure was followed for a similar time period on traditional medications. A panel of seven delayed hypersensitivity skin tests were placed at 6-to 12-month intervals on the patient's forearm. Seventy percent of all CHF patients were anergic (unable to T he rationale for the use of a a-blocker in treatment of patients with congestive heart failure (CHF) mainly has to do with its inhibition of the adverse effects associated with long-term activation of the sympathetic nervous system. These effects, including vasoconstriction, activation of the renin-angiotensin system, myocardial 13-adrenergic receptor downregulation, and direct cardiotoxicity, are all believed to contribute to the spiraling downhill course as the disease progresses. [1] [2] [3] [4] [5] [6] Although recent reports have proven fl-blocker treatment to be efficacious in some patients with CHF,7-15 its exact mechanism of benefit is unknown, causing other investigators to examine the "catecholamine-heart failure hypothesis" for other links to disease pathophysiology. 16 One of these potential links is the effect of the sympathetic nervous system on immune function. CHF and heightened sympathetic nervous activity share certain characteristics with respect to immune alterations. Both conditions are associated with mitigation of suppressor T-cell function, natural killer activity, diminished mitogen responsiveness, and interleukin (IL)-2 function.17-30 Additionally, both conditions are associ-ated with increased autoantibody production. [31] [32] [33] [34] [35] This leads us to consider whether the sympathetic overactivity leads to immune alterations that might contribute to progression of left ventricular dysfunction in the presence of heart failure.
The goal of the present study is to describe the changes in lymphocyte populations and cell-mediated immunity after treatment of CHF patients with metoprolol.
Methods

Patients
The following study protocol was approved by the University of California San Diego committee for investigations involving human subjects. Informed consent was obtained from each subject.
Metoprolol Group
We studied 15 patients from the San Diego Veterans Administration Medical Center (age range, 42 to 78 years; average age, 65 +4) with a history of CHF of at least 5 years' duration who were New York Heart Association (NYHA) class II-IV and taking conventional treatment: digitalis, diuretics, converting enzyme inhibitors (n=10), hydralazine (n=3), or nitrates (n=2). Ten patients were known to have occlusive coronary artery disease as shown by either coronary angiography or a well-documented myocardial infarction. Five patients were classified as having idiopathic cardiomyopathy. Left ventricular ejection fraction determined by equilibrium gated radionuclide ventriculography averaged 24+4%.
We wanted to maximize our changes of improving left ventricular dysfunction so that we could analyze changes in immune parameters more completely, therefore we biased our selection whenever possible to those patients we suspected might have a better outcome with treatment, that is, those with higher heart rates at baseline (mean, 98 ± 10 beats per minute).
After initial blood drawing and skin testing, patients were given a test dose of metoprolol 5 mg po BID. If the patient tolerated this dose, it was increased weekly by 5 to 10 mg to a maximum of 50 mg po BID. Patients who could not tolerate a minimum of 25 mg BID were exluded from further metoprolol treatment.
Control Group
While each patient given metoprolol served as their own control, we also studied a group of 15 patients with CHF with similar characteristics as the treated group with respect to age (age range, 44 to 77 years; average age, 67±4), ejection fraction (23±5%), and NYHA classification. These patients were all taking digitalis, diuretics, and vasodilators but had a contraindication to p3-blockers (chronic obstructive pulmonary disease, claudication, and/or drug-induced bradycardia), were unable to tolerate metoprolol 25 
Concanavalin A-Stimulated Proliferation
Sterile isolated mononuclear leukocytes were resuspended in RPMI medium supplemented with 25 ,ug/mL gentamicin, 2 mmol/L glutamine, and 20% fetal calf serum at a final density of 106 cells/mL; 150 ,uL of the cell suspension was transferred to each well of a 96-well, flat-bottomed plate. In some wells, concanavalin A (4.5, 9, 18, or 36 gg/mL) was present. Cells were incubated for 4 days in a humidified incubator with 95% air/5% carbon dioxide. During the last 16 hours of incubation, 2 ,uCi of 3H-thymidine dissolved in 20 ,uL of RPMI medium was added to each well. At the end of the incubation period, the cells were harvested over glass filters, size C (GF/C). The filters were washed with 10 pL of water, placed into vials, and 4.5 mL of Liquiscint (National Diagnostics, Inc) was added. The incorporated radioactivity was quantified in a liquid scintillation counter. Each point was assessed in quadruplicate in each experiment.
Interleukin-2 Receptor Expression
Sterile isolated mononuclear leukocytes were suspended in supplemented RPMI medium (see above) in the absence and presence of concanavalin A (18 ,ug/mL). After 48 hours, the cells were centrifuged and the expression of IL-2 receptors was determined fluorometrically by means of anti-CD 25 antibodies.
Catecholamines
Plasma catecholamine levels were measured radioenzymatically by the method of Durret and Ziegler. 37 
Data Analysis
Data shown are mean±SEM for the given number of patients for the experimental observation. The significance of differences were assessed as change from baseline for metoprolol-treated groups as well as conservatively treated patients using two-tailed paired t tests and ANOVA with Bonferroni corrections when necessary. Additionally, between-group analysis was performed on several immunologic parameters.
Results
Skin Tests
The average dose of metoprolol was 38+5 mg BID. Before treatment with metoprolol, 11 of 15 patients (73%) were anergic (<2 positive skin tests) ( Table 2) . nevertheless suggested benefits in certain patients with heart failure, including improvement in NYHA functional class and hemodynamic state, increase in ejection fraction, and a reduction of symptoms. Recently, the Metoprolol in Dilated Cardiomyopathy Trial was completed, which was a placebo-controlled study prospectively studying the effect of long-term /3-blockade with metoprolol on total mortality and need for heart transplantation.38 There was an estimated reduction in the sum of death and need for heart transplantation by metoprolol of 34%.
While studies are beginning to show a variety of propitious effects, we remain puzzled by the mechanism for these beneficial effects. The results of the present study point to a plausible hypothesis that the sympathetic nervous system has a role in the progression of heart failure in part through an immune-mediated mechanism.
Sympathetic Nervous System
Regulation of Immunity We recently found a marked reduction in the number of circulating lymphocytes as well as a decrease in natural killer and T-suppressor/cytotoxic cells and an increase in the T-helper-T-suppressor/cytotoxic ratio in a large group of patients with heart failure.17 Upon further characterization of these patients, we found that alterations in the circulating lymphocytes of patients with CHF were not related to the cause of the disease but rather to its severity and could in fact be correlated with plasma norepinepherine levels. Moreover, the alterations in the patients with CHF were identical with those observed after treatment of healthy subjects with the /,2-agonist terbutaline. 4 This was an unblinded study in which patients treated with metoprolol served as their own controls with regard to cardiac and immune function. We specifically recruited patients most likely to benefit by /3-blocker treatment, that is, those with an elevated heart rate (unpublished observations and Reference 60). Thus, our metoprolol patients cannot be compared directly with patients given standard treatment. There were, however, patients in the standard treatment group who had heart rates > 100 but who could not take metoprolol for other reasons (chronic obstructive pulmonary disease, claudication) and remained anergic despite standard treatment.
Although our data support the concept that sympathetic overactivity led to immune abnormalities, which led to progression of heart failure, we cannot prove a direct cause-and-effect relation. It is possible that the improvement in skin test status, T-cell function, and IL-2 receptors may occur independent of the improvement in ejection fraction. It is possible that with the improvemnent in ventricular function, patients became less "ill," which in and of itself might have affected outcome of some parameters of immune function. Nonetheless, the association with change in ejection fraction to immune status and the lack of such change in patients not treated with 13-blockers suggests more than a causal relation. We believe that it is not just the improvement of left ventricular function that changes immune parameters. We recently performed a study in which we treated a group of normal patients with propranolol. 61 We found that even with normal catecholamines, there was some enhancement of circulating T cells as well as an increase in concanavalin A-stimulated lymphocyte proliferation and IL-2 formation.
Conclusions
Our study shows that treatment of patients with CHF of either ischemic or idiopathic etiology with metoprolol resulted in improved parameters of cell-mediated immunity, especially the response to skin testing, and correlated with changes in ejection fraction. Additionally, there were increases in natural killer cell population, increase in T-suppressor/cytotoxic cells, and a trend toward increased mitogen proliferation and IL-2 receptor number. We believe that clinical improvement seen in patients taking 13-blockers may in part be due to a blockade of sympathetic-induced immune abnormalities. If this is the case, then further investigation into the role of immunologically mediated progression of left ventricular dysfunction is indicated.
